, June 23, 2015. Both funds track the Nasdaq Biotechnology Index.
“We’re pleased to expand our suite of biotech ETFs listed on Nasdaq,” said Michael L. Sapir, cofounder and CEO of ProShares Advisors, LLC, advisor to ProShares. “We now offer investors four ETFs providing magnified or inverse exposure to the Nasdaq Biotechnology Index, including the first and only 3x ETF on the index.”
ProShares is the world’s largest provider of geared ETFs. Geared ETFs are designed to offer knowledgeable investors the opportunity to act on their views, whether it’s hedging against downturns with inverse ETFs or using a leveraged ETF to get magnified exposure to a benchmark.
UBIO seeks to provide 3x and ZBIO seeks to provide -3x the daily performance of the Nasdaq Biotechnology Index, before fees and expenses. The Nasdaq Biotechnology Index is a modified capitalization weighted index that includes Nasdaq-listed companies classified as either biotechnology or pharmaceutical.
“We are thrilled to add UBIO and ZBIO to the ProShares product suite listed on The Nasdaq Stock Market,” said Jeff McCarthy, Vice President and Head of ETP Listings at Nasdaq. “These two products join the ProShares Ultra Nasdaq Biotechnology ETF (Symbol: BIB) and ProShares UltraShort Nasdaq Biotechnology ETF (Symbol: BIS), all benchmarked to the Nasdaq Biotechnology Index (Symbol: NBI). These launches demonstrate how Nasdaq can provide clients with turn-key solutions for passive products supporting both listing and index strategy.”
Nasdaq operates an efficient platform for successfully introducing a product suite into one of the single largest pools of liquidity, including market participants which represent a full spectrum of investors. ETF issuers benefit from an end-to-end solution that provides ongoing product support including index licensing, listings opportunities, data offerings and trading services. As the home to some of the world’s most innovative ventures, Nasdaq generates opportunities for issuers to access new markets and deliver new concepts that change the way the industry develops, manages and applies ETFs.
ProShares offers the nation’s largest lineup of alternative ETFs. They help investors to go beyond the limitations of conventional investing and face today’s market challenges. ProShares helps investors build better portfolios by providing access to alternative investments delivered with the liquidity, transparency and cost effectiveness of ETFs. Their wide array of alternative ETFs can help you reduce volatility, manage risk and enhance returns.
Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today’s global capital markets. As the creator of the world’s first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world’s securities transactions. Nasdaq is home to more than 3,500 listed companies with a market value of approximately $9.5 trillion and more than 10,000 corporate clients. To learn more, visit: nasdaq.com/ambition or business.nasdaq.com.
Cautionary Note Regarding Forward-Looking Statements
The matters described herein contain forward-looking statements that are made under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements about Nasdaq and its products and offerings. We caution that these statements are not guarantees of future performance. Actual results may differ materially from those expressed or implied in the forward-looking statements. Forward-looking statements involve a number of risks, uncertainties or other factors beyond Nasdaq’s control. These factors include, but are not limited to factors detailed in Nasdaq’s annual report on Form 10-K, and periodic reports filed with the U.S. Securities and Exchange Commission. We undertake no obligation to release any revisions to any forward-looking statements.
Nothing contained herein should be construed as investment advice from Nasdaq, either on behalf of a particular financial product or an overall investment strategy. Nasdaq makes no recommendation to buy or sell any financial product or any representation about the financial condition of any company or fund. Investors should undertake their own due diligence and carefully evaluate financial products before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.